In the 1950s thalidomide was a novel therapeutic agent that failed to control epileptic fits as anticipated from animal studies. However, it caused such drowsiness that it was ultimately marketed in 1958 as a sedative.' Its promotion ironically emphasized its safety as overdoses in animal tests failed to cause death. 2 In 1959 a single case report of a rare congenital abnormality, namely phocomelia, in a female infant born to a young primigravida was published.3 There followed a burst of similar reports in the medical literature and, in 1961, the connection between thalidomide and teratogenesis, particularly phocomelia, was established.4'5 Other recognized thalidomide birth defects include duodenal stenosis, oesophageal fistulae, neural tube abnormalities, micro-opthalmia, deformities ofthe pinna of the ears and mid-line haemangiomas.6 These abnormalities occurred following ingestion of thalidomide during the 35th-SOth day of pregnancy,7 affecting an estimated 12,000 babies worldwide in the late 1950s to early 1960s.
Peripheral neuropathy is the other major side effect of thalidomide and has received far less publicity. Three case reports appeared between 1960 and 19618-10 suggesting that peripheral neuritis was associated with thalidomide therapy and, in 1961, Fullerton" described 13 patients who had developed a predominantly sensory peripheral neuropathy with mild proximal muscle weakness whilst taking thalidomide as a night sedative.
The teratogenic potential of thalidomide led to its withdrawal *in the UK. The therapeutic benefits of thalidomide must be weighed against the tragedy of the 1960s. Currently in the UK thalidomide is being prescribed in hospitals on a 'named patient' basis, in accordance with Section 9(1) of the Medicines Act4' to a small number of patients who have exhausted other therapeutic options. Guidelines are presented to enable the highest standards ofsafety to be adopted in the use of thalidomide, and these recommendations will require revision and modification as further clinical experience with thalidomide is gained. Clearly in each individual patient the risks of teratogenicity and peripheral neuropathy must be carefully addressed both before and during treatment.
The use of thalidomide in fertile women remains controversial and must be restricted to small numbers in highly controlled situations, where both patients and doctors fully comprehend and accept the responsibilities and risks, which must include the possibility of contraceptive failure.42 In the USA attempts at controlling the prescription of drugs with teratogenic risk, such as the extreme efforts of Roche over the use of isotretinoin in pregnant women in the USA, has been notable for its lack of success.43 In the UK the use of isotretinoin is restricted to prescribing by hospital consultants only. The risk of peripheral neuropathy remains, particularly with chronic treatment, but with regular monitoring of the amplitude of sensory nerve action potentials, subclinical neuropathic changes can be detected." Provided the recommendations for the use of thalidomide are closely followed then this drug can be used safely.
Thalidomide provides an important therapeutic option in patients with a number of conditions whose disease cannot be as satisfactorily controlled by other means, and potentially may be increasingly prescribed because of its value in the growing fields of GVHD'6 and HIV. 17 The effective dose of thalidomide is not known, but experience in oral and genital ulceration suggests that small doses are effective. Although there are no product licences for thalidomide in this country, its use on a 'named patient' basis will allow its continued use for those patients for whom it remains an important therapeutic option by clinicians with the necessary expertise. The guideline is designed to promote the safest possible use of thalidomide.
